CRDL - Cardiol Therapeutics Inc. News

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with

Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the A

The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publ

Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Su

TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30

TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol

12 Health Care Stocks Moving In Wednesday's After-Market Session

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Invest

TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the Americ

Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recu

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the

Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwe

Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)

Corcept Therapeutics (NASDAQ: CORT - Get Free Report) and Cardiol Therapeutics (NASDAQ: CRDL - Get F

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in L

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX:

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50%

Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conferenc

Cardiol Therapeutics (NASDAQ: CRDL) used a presentation at TD Cowen's 46th Annual Healthcare Confere

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (T

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (T

Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell?

Cardiol Therapeutics Inc. (TSE: CRDL - Get Free Report) shares fell 7.1% during mid-day trading on T

Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – What’s Next?

Cardiol Therapeutics Inc. (TSE: CRDL - Get Free Report) shares fell 7.1% during trading on Thursday.

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment

Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TS

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TS

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TS

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Tria

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patien

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and im

Stocks That Hit 52-Week Lows On Friday

On Friday morning, 446 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 838 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

On Friday, 404 stocks made new 52-week lows.